Book icon with persian name of Pubnito
  • Store
  • Library
  • Your Cart


    Total Items:0

    View Cart

    Frontiers in Clinical Drug Research - Anti Infectives: Volume 7

    Frontiers in Clinical Drug Research - Anti Infectives: Volume 7

    Atta-ur-Rahman

    "Frontiers in Clinical Drug Research – Anti infectives is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of infectious diseases. The scope of the book series covers a range of topics including the chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs employed in the treatment of infectious diseases. Reviews in this series also include research on multi drug resistance and pre-clinical / clinical findings on novel antibiotics, vaccines, antifungal agents and antitubercular agents. Frontiers in Clinical Drug Research – Anti infectives is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of anti infective drug discovery and epidemiology. The seventh volume of this series features these interesting reviews: - Nucleic acid and peptide aptamers as potential antiviral drugs - Host-directed, antibiotic-adjuvant combination, and antibiotic-antibiotic combination for treating multidrug-resistant (mdr) gram-negative pathogens - Bioactive substances as anti-infective strategies against clostridioides difficile - Anti-toxoplasma drug discovery and natural products: a brief overview - Development of antimalarial and antileishmanial drugs from amazonian biodiversity" "Frontiers in Clinical Drug Research – Anti infectives is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of infectious diseases. The scope of the book series covers a range of topics including the chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs employed in the treatment of infectious diseases. Reviews in this series also include research on multi drug resistance and pre-clinical / clinical findings on novel antibiotics, vaccines, antifungal agents and antitubercular agents. Frontiers in Clinical Drug Research – Anti infectives is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of anti infective drug discovery and epidemiology. The seventh volume of this series features these interesting reviews: - Nucleic acid and peptide aptamers as potential antiviral drugs - Host-directed, antibiotic-adjuvant combination, and antibiotic-antibiotic combination for treating multidrug-resistant (mdr) gram-negative pathogens - Bioactive substances as anti-infective strategies against clostridioides difficile - Anti-toxoplasma drug discovery and natural products: a brief overview - Development of antimalarial and antileishmanial drugs from amazonian biodiversity"

    Book Format

    Book License

    $ 79.00

    Reviews

    Rating Snapshot

    Select a row below to filter reviews.

    0

    0

    0

    0

    0

    0

    Overall

    Average Customer Ratings

    Review for this Book

    Share your thoughts with other readers

    More Information

    Description of Frontiers in Clinical Drug Research - Anti Infectives: Volume 7

    "Frontiers in Clinical Drug Research – Anti infectives is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the

    Additional Information

    Vendor

    Publish Date

    2021 Jul 02

    Authors
    Atta-ur-Rahman

    ISBN

    9789814998093

    About the authors

    Atta-ur-Rahman
    Atta-ur-Rahman
    Atta-ur-Rahman

    Table of content

    logo

    English

    Powered by PUBNiTO | © 2024 Notion Wave Inc.